Advertisement
Screener

Fortress Biotech, Inc. (FBIO) Adjustments to Additional Paid in Capital, Warrant Issued

2.1 / 5 stars · 40/95 Roast Me

Fortress Biotech, Inc. Adjustments to Additional Paid in Capital, Warrant Issued

Fortress Biotech, Inc. (FBIO) reported Adjustments to Additional Paid in Capital, Warrant Issued of $13.62 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.

Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2019-03-18

  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2018-09-30 was $0.00.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2017-12-31 was $0.00.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2017-09-30 was $0.00.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2017-06-30 was $544.00K.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2017 was $750.00K, a 5.42% decline from fiscal 2016.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2016 was $793.00K, a 29.36% increase from fiscal 2015.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2015 was $613.00K.
  • Fortress Biotech, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2011 was $2.69M.
Period endAdjustments to Additional Paid in Capital, Warrant Issued 3 monthAdjustments to Additional Paid in Capital, Warrant Issued 6 monthAdjustments to Additional Paid in Capital, Warrant Issued 9 monthAdjustments to Additional Paid in Capital, Warrant Issued 12 month
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$13.62M
10-Q · filed 2018-11-09
2018-06-30$13.62M
10-Q · filed 2018-08-09
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18
$0.00
derived: sum of 2 quarters · filed 2019-03-18
$544.00K
derived: sum of 3 quarters · filed 2019-03-18
$750.00K
10-K · filed 2019-03-18
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
$544.00K
derived: sum of 2 quarters · filed 2017-11-09
$750.00K
10-Q · filed 2017-11-09
2017-06-30$544.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09
$750.00K
10-Q · filed 2017-08-09
2017-03-31$206.00K
10-Q · filed 2017-05-10
2016-12-31$793.00K
10-K · filed 2018-03-16
2015-12-31$613.00K
10-K · filed 2018-03-16
2011-12-31$2.69M
10-K · filed 2014-03-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
ALX ONCOLOGY HOLDINGS INC (ALXO)United States$0.187B-3.52
PepGen Inc. (PEPG)United States$0.186B-1.73
AN2 Therapeutics, Inc. (ANTX)United States$0.185B-4.84
Organogenesis Holdings Inc. (ORGO)United States$0.182B-3.70
Zentalis Pharmaceuticals, Inc. (ZNTL)United States$0.196B-2.48
ORAMED PHARMACEUTICALS INC. (ORMP)$0.199B1.13
Nkarta, Inc. (NKTX)United States$0.205B-1.73
Tonix Pharmaceuticals Holding Corp. (TNXP)United States$0.166B-1.34
Minerva Neurosciences, Inc. (NERV)United States$0.165B-0.66
ADC Therapeutics SA (ADCT)$0.163B-1.39